Tenofovir and emtricitabine can suppress hepatitis B among patients in the immune-tolerant stage, according to a study presented at a liver disease research meeting in Europe. Researchers tracked 126 HBV patients and found that 76% of those who took the tenofovir-emtricitabine combination for four years experienced viral suppression compared with 55% of those who received tenofovir alone. Few patients, however, regained their immune response to the pathogen, and among participants who stopped taking the drugs, viral loads returned to pre-study levels.
HIV combo therapy suppresses HBV in some patients
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan